中国生命科学行业创新与未来发展论坛 / Swiss Healthcare Innovation in China: A Forward Overview on Business and Policies

尊敬的中国瑞士商会会员及朋友，

中国的生命科学行业正在经历快速和变革性的增长，为瑞士制药和医疗科技公司提供了巨大的机遇。 作为全球生命科学领域的创新枢纽，瑞士企业在技术和研发方面拥有显著优势。 鉴于中国生命科学行业的蓬勃发展，中国瑞士商会诚邀您参加我们即将于2023年9月19 日在北京耶鲁中心举办的闭门活动"瑞士医疗在中国的创新：商业与政策的前瞻性概述" 。该活动由中国瑞士商会 (SwissCham) 生命科学委员会 (LSC) 主办。 本次活动重点探讨中国生命科学行业的市场发展和重点政策，为促进交流、学习和建立伙伴关系提供重要平台。

中国瑞士商会生命科学委员会旨在提高瑞士制药和医疗科技公司在中国的知名度并促进其发展。该成员包括诺华、盖氏、赫尔森、罗氏诊断、龙沙、倍力曼、医沛生、瑞士EMS、罗氏诊断、彼岸、索诺瓦和士卓曼，致力于政策、市场趋势及数字化转型等领域的活动、圆桌讨论和等活动。中国瑞士商会生命科学委员会得到了瑞士驻华大使馆大使白瑞谊阁下和瑞士驻华使馆经济、金融与商务处主任Martin Matter的背书。

在首次活动之际，瑞士商会生命科学委员会为您呈现多元活动，包括主题为"带量采购（VBP）和本地化"的演讲，以及由行业专家主持的小组讨论，主题为" 本地化"以及公司如何主动将不断变化的政府法规融入其本地化战略，以确保长期合规性。最后，中国瑞士商会生命科学委员会成员公司将在本次活动中分享他们在中国开展业务的经验。

我们期待9月19日与您见面。

*****

Dear Members and Friends of the SwissCham,

The life science industry in China is undergoing rapid and transformative growth, presenting immense opportunities for Swiss Pharma and MedTech companies. As a pivotal hub of innovation in the global life science landscape, Switzerland's enterprises possess remarkable advantages in technology and research and development. In light of China's dynamic life science industry expansion, we are delighted to invite you to our upcoming closed-door event "Swiss Healthcare Innovation in China: A Forward Overview on Business & Policies" on September 19, 2023, in Yale Center Beijing, hosted by the SwissCham Life Sciences Committee (LSC) of the Swiss-Chinese Chamber of Commerce (SwissCham). This event focuses on learning about and understanding the market development and key policies in China's life sciences industry. It serves as an important platform to facilitate exchange, learning, and partnerships.

The SwissCham Life Sciences Committee aims to elevate the visibility and facilitate the growth of Swiss Pharma and MedTech companies in China. With members including Novartis, Geistlich, Helsinn, Roche, Lonza, BeliMed, Ypsomed, EMS, Roche Diagnostics, BienAir, Sonova, and Straumann, the SwissCham LSC is committed to orchestrating activities, roundtable discussions, and other initiatives in the domains of policies, market trends, and digital transformation. The SwissCham Life Sciences Committee has received the endorsement of His Excellency Ambassador Juerg Burri at the Embassy of Switzerland in China and Martin Matter, Head of Economic, Finance, and Commercial Affairs.

On the occasion of its first event, the SwissCham Life Sciences Committee has organized a comprehensive program, including a presentation on the topic of "Volume-Based Procurement (VBP) and Localization", a panel discussion hosted by industry experts featuring the topic on "Localization" and how companies can proactively integrate evolving government regulations into their localization strategies to ensure long-term compliance. Finally, the event will host SwissCham Life Sciences Committee member companies to share their experiences while conducting business in China.

We are looking forward to meeting you on September 19.

Your SwissCham Team